A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-27 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Upper Crust is an international chain of baguette restaurants concentrated along commuter routes. The outlets are commonplace in stations and terminals. There are branches at the central railway station in Oslo and Elkjøp Megastore Lørenskog, Norway. Since September 2008, there are also three units in Stockholm, Sweden – two at the central railway station and one at the nearby bus terminal, Cityterminalen. There is also one in the Gothenburg Central Station, and one in Euston Station, London. The company has started to expand into shopping centres, with a new store at Bridgend Designer Outlet, South Wales. There are also branches in airports, including Cairo Airport, Tromsø Airport, Trondheim Værnes Airport, Oslo Airport Gardermoen, Helsinki Airport, Toronto Airport, Sofia Vasil Levski Airport, George Bush Intercontinental Airport and Gran Canaria Airport. They were located in Australia too in the past, at places such as Circular Quay.
=== Osteoinduction === Osteoinduction involves the stimulation of osteoprogenitor cells to differentiate into osteoblasts that then begin new bone formation. The most widely studied type of osteoinductive cell mediators is bone morphogenetic proteins (BMPs). A bone graft material that is osteoconductive and osteoinductive will not only serve as a scaffold for currently existing osteoblasts but will also trigger the formation of new osteoblasts, theoretically promoting faster integration of the graft.
== References == "Wife Stricken in War-Torn China, Husband Develops Own Insulin Lab". Kentucky New Era. 1951-11-06. p. 14. Mclean, Radha (2002), Eva's Insulin Hirsch, James (2006), Cheating Destiny: Living with Diabetes, America's biggest epidemic, Boston: Houghton Mifflin Co., ISBN 0-618-51461-9
=== Clinical trials === PL9643, an ophthalmic solution, is being tested in phase 3 clinical trials to determine safety and efficacy in patients with dry eye. PL9643 activates MC1R, MC3R, MC4R and MC5R. Completed Phase 2 studies demonstrated positive results for the treatment of dry eye disease. Dersimelagon (MT-7117) is an orally administered MC1R agonist being tested in phase 3 clinical trials to evaluate safety and tolerability in patients with erythropoietic protoporphyria or X-linked protoporphyria. Resomelagon (AP1189) is an orally administered MC1R and MC3R agonist being tested in three phase 2 clinical trials to study safety and efficacy in patients with rheumatoid arthritis and idiopathic membranous nephropathy.
Sources: en.wikipedia.org
=== Binary, cationic === Group 2 elements form [M(CO)8]+ (M = Ca Sr, Ba), characterized in gas phase by mass spectrometry and vibrational spectroscopy. Group 3 elements form [Sc(CO)7]+ and [Y(CO)8]+ in gas phase. Group 7 elements as monocations resemble neutral group 6 derivative [M(CO)6]+ (M = Mn, Tc, Re). Group 8 elements as dications also resemble neutral group 6 derivatives [M(CO)6]2+ (M = Fe, Ru, Os).
== Products == Several types of products, including retail bags, carton liners, bin bags, lidding films and flow pack have been developed from MA/MH films and are commercially available. Each product type is uniquely engineered for the specific produce type (and in some cases, the produce variety) to be packaged. This is done through a rigorous process of developing, testing, adjusting and retesting each MA\MH product both in the lab and in commercial trials. This meticulous process is repeated for each combination of produce and packaging type because of the many factors involved in developing a successful MA/MH packaging. These factors are "storage and shipment temperature, product respiration rate and quotient, response to levels of CO2, O2 and humidity, and product weight. Hence, film packaging that is adequate for consumer packages is not always suitable for bulk packaging and vice versa."
Some of these differences include the "vigor" or speed of fermentation, temperature tolerance, the production of volatile sulfur compounds (such as hydrogen sulfide) and other compounds that may influence the aroma of the wine. In modern winemaking, winemakers have the option to select from a diverse range of yeast strains, each offering distinct characteristics that influence the wine's sensory profile. These strains are readily available for purchase from specialized suppliers. Winemakers can now easily access yeast strains that accentuate desirable features in wine, such as aromatic compounds, mouthfeel, and fermentation kinetics. This commercial availability of yeast strains has revolutionized the art of winemaking by allowing for more precise control over the fermentation process and the resultant wine's character.
== Function == Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been shown to be involved in many different cellular functions, such as apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.
transcytosis The transport of molecules across the interior of a cell, i.e. through the cytoplasm, especially a polarized cell such as an epithelial cell with contrasting apical and basal surfaces, thereby providing a spatially oriented transport system. Molecules undergoing transcytosis are usually contained within vesicles.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.